View abstract

Cet abstract a été assigné à session FRO: Fund for Research in Ophthalmology
TitreFRO: Subconjunctival bevacizumab enhances the antifibrotic effect of MMC and allows to reduce its exposure time to improve safety
Abstract Nr.1030
ButTo determine the most optimal administration route of bevacizumab after GFS and to investigate whether reducing the exposure time and/or dose of MMC in combination with bevacizumab could improve surgical outcome with a lower incidence of side effects.
MéthodesIn the first experiment, mice were operated and received a subconjunctival (SC), intracameral (IC) or intravitreal (IV) injection of bevacizumab (25µg). Bevacizumab plasma levels were measured using ELISA. In the second experiment, the combination of MMC and bevacizumab was compared to MMC in operated mice. Surgical sponges soaked in MMC 0.02% and 0.01% were investigated and exposed to the sclera for 1 or 2 min. Treatment outcome was studied by clinical investigation of the bleb.
RésultatsTreatment using a SC, IC or IV bevacizumab equally improved surgical outcome. Importantly, bevacizumab was detected at relatively high levels in plasma shortly after IV injection, whereas minimal bevacizumab absorption was detected only from day 4 after SC or IC administration. Administration of SC bevacizumab combined with 1 or 2 min of MMC 0.02% equally improved bleb area, as compared to MMC 0.02% alone. The combination of bevacizumab and 1 min exposure of MMC 0.01% also significantly improved surgical outcome (versus 1 min MMC 0.01%), although to a lesser extent than the combination with MMC 0.02% for 1 min. Importantly, 25% of the eyes treated for 2 min with MMC showed corneal toxicity, whereas this was not the case after 1 min of administration.
ConclusionAdjunctive subconjunctival bevacizumab allows to reduce the administration time of MMC 0.02%, thereby eliminating its toxic effects on the cornea while maintaining the beneficial effects on surgical outcome.
Auteur 1
NomVAN BERGEN
InitialesT
InstitutKUL
VilleLeuven
Auteur 2
NomVANDEWALLE
InitialesE
InstitutKUL
VilleLeuven
Auteur 3
NomMOONS
InitialesL
InstitutKUL
VilleLeuven
Auteur 4
NomSTALMANS
InitialesI
InstitutKUL
VilleLeuven
top ^